Analysis of Rates of Brain Metastases and Association With Breast Cancer Subtypes in Ontario, Canada

Authors:

Abstract
Brain metastases (BRM) are a major cause of morbidity and mortality in women with breast cancer.1-5 Women with metastatic ERBB2 (formerly HER2)–positive and triple-negative breast cancer (TNBC) have a particularly high propensity to develop intracranial disease; in fact, over one-third of these women develop BRM during their lifetime.6-10 Although some systemic therapies have demonstrated intracranial activity, the mainstay of therapy for patients with breast cancer BRM remains local therapy, with radiation in the form of whole brain radiotherapy (WBRT) and/or stereotactic radiosurgery (SRS), as well as surgery in select cases.

This publication has 38 references indexed in Scilit: